Granisetron
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Granisetron: From Antiemetic Use to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist, established for controlling nausea and vomiting associated with chemotherapy and other emetogenic triggers. The TxGNN model predicts it may be effective for manic bipolar affective disorder, but this is currently a pure computational prediction with 0 clinical trials and 0 publications supporting the link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack — the drug is not currently marketed in the UK and no licence-derived indication text is available |
| Predicted New Indication | Manic bipolar affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal, structured mechanism-of-action data is not available for this candidate (flagged as a data gap in the evidence pack). However, the supporting rationale accompanying this prediction consistently describes granisetron as a selective 5-HT3 (serotonin type 3) receptor antagonist — the same pharmacological class as ondansetron, and the basis of its established antiemetic use in controlling chemotherapy-induced and other forms of nausea and vomiting.
The proposed link to manic bipolar affective disorder rests on an indirect, mechanistic hypothesis rather than direct clinical observation: small studies of other 5-HT3 antagonists (notably ondansetron) have explored adjunctive effects on mood stabilisation, on the theory that modulating central serotonergic transmission may influence affective symptoms. TxGNN’s knowledge-graph model appears to be drawing on this class-level association rather than any granisetron-specific evidence.
It is important to note that no clinical trials or published studies of granisetron itself in bipolar disorder currently exist. The mechanistic plausibility is therefore theoretical and should be treated as a research hypothesis rather than an evidence-supported repurposing candidate at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
This drug currently holds no UK marketing authorisation on file (market status: Not Marketed, 0 licences recorded in this evidence pack). No product-level dosage form or approved indication text is available for tabulation.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: key warnings, contraindications and drug-drug interaction data for this candidate are currently unavailable in this evidence pack — this is flagged as a Blocking data gap, meaning it prevents even an initial safety screen from being completed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 — the manic bipolar affective disorder association is supported only by TxGNN’s knowledge-graph score and an indirect mechanistic rationale, with zero clinical trials or literature.
- A Blocking-severity data gap on safety (no verified warnings/contraindications) means this candidate cannot yet proceed to even an initial safety review.
To proceed, the following is needed:
- Official UK/manufacturer SmPC data (warnings, contraindications, drug interactions) to clear the Blocking safety gap
- Confirmed mechanism-of-action documentation (e.g. via DrugBank API) to support or refute the mechanistic rationale
- Preclinical or mechanistic studies specifically testing granisetron (not just the 5-HT3 antagonist class) in mood/affective disorder models
- Confirmation of the drug’s original indication and regulatory history, since no licence data is currently on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.